• 1
    Peters WP, Shpall EJ, Jones RB, et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988; 6: 13681376.
  • 2
    Crown J, Raptis G, Hamilton N, Fennelly D, Vahdat L, Norton L. High-dose chemotherapy of breast cancer: current status and developmental strategies. Eur J Cancer. 1995; 31: 809811.
  • 3
    Wani MC, Taylor HL, Wall ME, Coggon P, Mophail AT. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agents from Taxus brevifolia. J Am Chem Soc. 1971; 93: 23252327.
  • 4
    Kingston DGI, Samaranayake G, Ivey GA. The chemistry of paclitaxel, a clinically useful anticancer agent. J Nat Prod. 1990; 53: 112.
  • 5
    Kroger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev. 1999; 25: 279291.
  • 6
    Murad AM, Guimaraes RC, Amorim WC, Moriei AC, Ferrera-Filho AF, Schwartsmann G. Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. Breast Cancer Res Treat. 1997; 45: 4753.
  • 7
    Burkert H. Ifosfamide. European perspective. Semin Oncol. 1982; 9(suppl 1): 2835.
  • 8
    Seidman AD, Reichman BS, Crown JP, et al. Paclitaxel as secondary and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol. 1995; 13: 11521159.
  • 9
    Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol. 1995; 13: 20562065.
  • 10
    Munzone E, Capri G, Demichelli R. Activity of taxol by 3 h infusion in breast cancer patients with clinical resistance to anthracyclines. Eur J Cancer. 1993; 29A(suppl 6): 413.
  • 11
    Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994; 12: 16211629.
  • 12
    Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 18581867.
  • 13
    Clemons M, Leahy M, Valle J, Jayson G, Ranson M, Howell A. Review of recent trial of chemotherapy for advanced breast cancer: the taxens. Eur J Cancer. 1997; 13: 21832193.
  • 14
    Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel and docetaxel. Cancer Treat Rev. 1993; 19: 351386.
  • 15
    Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev. 1996; 22: 127142.
  • 16
    Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol. 1999; 17: 34033411.
  • 17
    Fountzilas G, Athanassiadis A, Kaloger-Fountzila A, et al. Paclitaxel by 3 h infusion and carboplatin in anthracycline resistant advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer. 1997; 33: 18931895.
  • 18
    Liombart-Cussac A, Spielmann M, Dohollou N, Le Cesne A, Rixe O. Cisplatinum-taxotere phase I/II trial in patients with anthracycline-resistant advanced breast cancer. Proc Am Soc Clin Oncol. 1997; 16: 629.
  • 19
    Klaassen U, Wilke H, Harstrick A, et al. Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second line treatment of metastatic breast cancer: results of a phase II study. Ann Oncol. 1998; 9: 4550.
  • 20
    Klaassen U, Wilke H, Seeber S. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in treatment of advanced breast cancer. Semin Oncol. 1996; 23(suppl 11): 3237.
  • 21
    Hortobagyi GN. Activity of ifosfamide in breast cancer. Semin Oncol. 1992; 19(suppl 12): 3641.
  • 22
    Becher R, Hofeler H, Kloke O, et al. Ifosfamide, methotrexate and 5-FU in advanced pretreated breast cancer. Semin Oncol. 1989; 16: 5659.
  • 23
    Walters RS, Holmes FA, Valero V, Esparza-Guerra L, Hortobagyi GN. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am J Clin Oncol. 1998; 21: 413415.
  • 24
    Bisagni G, Boni C, Manenti AL, et al. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study. Tumori. 1998; 84: 659661.
  • 25
    Bunnell CA, Thompson L, Buswell L, et al. A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer. 1998; 82: 561566.